Multithread effectively and personalize outreach to convert deals faster
Elevate social presence and drive business growth from social media
Identify and prioritize high-intent leads, and improve sales effectiveness
Find and connect with ICP attendees, and improve event outcomes
NeuroPace is a commercial-stage medical device company dedicated to transforming the lives of people suffering from epilepsy by reducing or eliminating the occurrence of disabling seizures. Their flagship product, the RNS® System, is the first and only FDA-approved brain-responsive neurostimulation system that delivers personalized, real-time treatment at the seizure source. By monitoring brain activity and responding with imperceptible stimulation, the RNS System offers a new level of control for patients with refractory epilepsy who have not responded to medication. NeuroPace is committed to advancing the understanding and treatment of neurological disorders through continuous innovation and data-driven insights derived from its extensive brain data platform.
Serves as the primary center for NeuroPace's corporate leadership, research and development, manufacturing, clinical operations, sales, and marketing efforts.
Modern facility likely equipped with state-of-the-art laboratories for medical device development, cleanroom environments for manufacturing, and collaborative office spaces designed to foster innovation.
A dynamic and mission-driven work environment focused on innovation in neurotechnology, scientific rigor, and a strong commitment to improving patient outcomes. The culture likely encourages collaboration, continuous learning, and a fast-paced approach typical of Silicon Valley med-tech companies.
Its Silicon Valley location provides access to a rich ecosystem of technological talent, research institutions, venture capital, and other medical technology companies, fostering innovation and partnerships.
NeuroPace's RNS System is currently FDA-approved and primarily marketed within the United States. The company focuses its commercial operations and direct patient treatment solutions on the U.S. market. While NeuroPace engages with the global neurology community through research, publications, and participation in international conferences, its direct sales and support infrastructure is concentrated in the U.S. Future international expansion would depend on obtaining regulatory approvals in other countries and regions.
455 N. Bernardo Ave
Mountain View
CA
USA
No additional office locations available.
Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.
As of April 2025, NeuroPace' leadership includes:
NeuroPace has been backed by several prominent investors over the years, including:
Over the past 12-18 months, NeuroPace has strengthened its leadership team with key appointments and promotions, including a new Chief Commercial Officer and promotions to Chief Clinical & Technical Officer and Chief Technology Officer, underscoring its commitment to commercial growth and technological innovation. No prominent C-suite departures were publicly announced during this period.
Discover the tools NeuroPace uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.
NeuroPace likely utilizes common corporate email address formats. The most probable patterns combine an employee's first initial and last name, or their full first name and last name separated by a dot.
[first_initial][last]@neuropace.com or [first].[last]@neuropace.com
Format
jdoe@neuropace.com
Example
80%
Success rate
GlobeNewswire • May 8, 2024
NeuroPace announced total revenue of $15.3 million for Q1 2024, a 29% increase year-over-year. The company reiterated its full-year 2024 revenue guidance of $70 million to $75 million....more
GlobeNewswire • April 25, 2024
NeuroPace, Inc. (Nasdaq: NPCE) announced that it would report financial results for the first quarter of 2024 after market close on Wednesday, May 8, 2024, followed by a conference call....more
GlobeNewswire • March 5, 2024
NeuroPace reported record total revenue of $17.0 million for the fourth quarter of 2023, representing a 40% increase over the prior year period. Full year 2023 total revenue was $60.6 million, a 34% increase....more
GlobeNewswire • February 20, 2024
NeuroPace announced the publication of new data from its real-world patient registry in the journal Epilepsia, showing continued significant and sustained reduction in seizure frequency in patients treated with the RNS System. The study included over 2,000 patients and reported a median 82% reduction in disabling seizures at 3+ years post-implant....more
See where a company’s workforce is located, by country or region.
View past and recent funding rounds with amounts and investors.
Understand company revenue estimates and financial scale.
Track active roles and hiring trends to spot growth signals.
Discover what a company offers—products, platforms, and solutions.
Get the company’s official SIC and NAICS classifications.
Analyze visitor volume, engagement, and top traffic sources.
Explore LinkedIn, Twitter, and other active social profiles.
Identify top competitors based on similar business traits.
Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.
Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.
Thousands of companies, including NeuroPace, are just a search away.